Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Sglt2 Inhibitors and Ampk: The Road to Cellular Housekeeping? Publisher Pubmed



Safaie N1 ; Masoumi S1, 2 ; Alizadeh S3 ; Mirzajanzadeh P4 ; Nejabati HR4 ; Hajiabbasi M5 ; Alivirdiloo V6 ; Basmenji NC4 ; Derakhshi Radvar A4 ; Majidi Z7 ; Faridvand Y1, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  2. 2. Cardiovascular Fellowship, Vanderbilt University of Medical center, Nashville, TN, United States
  3. 3. Department of Hematology, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  5. 5. Faculty of Medicine, Islamic Azad University of Tonekabon, Tonekabon, Iran
  6. 6. Ramsar Campus, Mazandaran University of Medical Sciences, Ramasr, Iran
  7. 7. Department of Medical Laboratory Science, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
  8. 8. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Cell Biochemistry and Function Published:2024


Abstract

Sodium-glucose co-transporter-2 (SGLT2) inhibitors, known as Gliflozins, are a class of Glucose-lowering drugs in adults with type 2 diabetes (T2D) that induce glucosuria by blocking SGLT2 co-transporters in the proximal tubules. Several lines of evidence suggest that SGLT2 inhibitors regulate multiple mechanisms associated with the regulation of varying cellular pathways. The 5′-adenosine monophosphate-activated protein kinase (AMPK) pathway plays an important role in metabolic homeostasis by influencing cellular processes. Recently, it has been shown that SGLT2 inhibitors can affect the AMPK pathway in differing physiological and pathological ways, resulting in kidney, intestinal, cardiovascular, and liver protective effects. Additionally, they have therapeutic effects on nonalcoholic fatty liver disease and diabetes mellitus-associated complications. In this review, we summarize the results of studies of AMPK-associated therapeutic effects of SGLT2 inhibitors in different organelle functions. © 2024 John Wiley & Sons Ltd.
Experts (# of related papers)